Korea Arlico Pharm Co (XKRX:260660) 3-Year EBITDA Growth Rate : -33.00% (As of Dec. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Korea Arlico Pharm Co 3-Year EBITDA Growth Rate?

Korea Arlico Pharm Co's EBITDA per Share for the three months ended in Dec. 2024 was ₩146.21.

During the past 12 months, Korea Arlico Pharm Co's average EBITDA Per Share Growth Rate was -74.10% per year. During the past 3 years, the average EBITDA Per Share Growth Rate was -33.00% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was -19.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 10 years, the highest 3-Year average EBITDA Per Share Growth Rate of Korea Arlico Pharm Co was 26.20% per year. The lowest was -66.40% per year. And the median was -4.40% per year.

Competitive Comparison of Korea Arlico Pharm Co's 3-Year EBITDA Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, Korea Arlico Pharm Co's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Korea Arlico Pharm Co's 3-Year EBITDA Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Korea Arlico Pharm Co's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Korea Arlico Pharm Co's 3-Year EBITDA Growth Rate falls into.

Save Embed

;

Save Embed

;

Korea Arlico Pharm Co 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Korea Arlico Pharm Co (XKRX:260660) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Korea Arlico Pharm Co 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Korea Arlico Pharm Co's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Korea Arlico Pharm Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Korea Arlico Pharm Co Ltd (XKRX:260660) » Definitions » 3-Year EBITDA Growth Rate

Traded in Other Exchanges

N/A

Address

7-21, Baumoe-ro 27-gil, Seocho-gu, Seoul, KOR

Website

http://www.arlico.co.kr

Korea Arlico Pharm Co Ltd is engaged in the business of manufacturing and selling pharmaceuticals products. The company offers products in the area of the circulatory system, antiplatelet, muscle relaxants, diabetes, antibiotic and chemotherapy, allergy and respiratory disease, ointment, vitamin and health supplements, digestive system, and metabolic disease. It provides products in various forms such as tablets, capsules, gel, and cream.

Korea Arlico Pharm Co Headlines

No Headlines